Alnylam Pharma (ALNY) Tops Q4 EPS by 2c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $145.79 --0%
Revenue Growth %: +33.0%
Financial Fact:
Net loss: -90.13M
Today's EPS Names:
SFST, VLTO, CLIR, More
Revenue Growth %: +33.0%
Financial Fact:
Net loss: -90.13M
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($1.32), $0.02 better than the analyst estimate of ($1.34). Revenue for the quarter came in at $17.5 million versus the consensus estimate of $10.95 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
- Option Care Health (OPCH) Tops Q1 EPS by 3c, provides guidance
- Sherwin-Williams (SHW) Misses Q1 EPS by 5c, provides guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
